Listen as AmerisourceBergen experts discuss the continuing evolution of the biosimilar marketplace and share how we are inspiring confidence and uptake among key stakeholders.

Live from Advanced Therapies Week with TrakCel

Feb 10th, 2022 25m 57s

The booming pipeline of cell and gene therapies, and their unique requirements, means both hope for patients and potential around eligibility and coverage barriers. We talk to experts from AmerisourceBergen and TrakCel about a new partnership f

More on PSAOs: Investing in independents

Jan 20th, 2022 8m 50s

We're joined again by AmerisourceBergen's Peter Kounelis to discuss how the right PSAO should invest in and advocate for independent pharmacies.

The evolution of the PSAO

Oct 27th, 2021 14m 10s

With independent pharmacy facing increasing pressures from the tight reimbursement landscape, how can the right contracting strategy help? Peter Kounelis, Vice President of Elevate Provider Network at AmerisourceBergen, joins us to discuss the

Insulin biosimilars part 2

Aug 31st, 2021 15m 38s

We’re discussing insulin biosimilars with Sean McGowan and Michelle Jesse from AmerisourceBergen’s biosimilars team, along with Brad Tallamy, Senior Director of Government Affairs at AmerisourceBergen. In part two of a two-part series on insuli

Insulin biosimilars part 1

Jul 26th, 2021 13m 46s

We’re revisiting the biosimilars market with Sean McGowan and Michelle Jesse from AmerisourceBergen’s biosimilars team, along with Brad Tallamy, Senior Director of Government Affairs at AmerisourceBergen. In part one of a two-part series on ins

ThinkLive Commercialization

May 13th, 2021 13m 3s

AmerisourceBergen recently hosted its first-ever manufacturer summit dedicated to commercialization strategy and market access. In this episode, hear highlights from the event.

Oct 20th, 2020 16m 20s

In our inaugural episode, we’re looking at the biosimilars market with Sean McGowan, Senior Director of Biosimilars at AmerisourceBergen. Sean will be joined by David Senior and Steve Miller to talk about the policy and reimbursement issues tha

Rate